A number of rare/genetic disease readouts are set this Q3 2025. Some of them are likely to move big. See table below for 6 of the anticipated readouts. 📈 📉 6 stocks likely to move big on rare/genetic disease readouts in Q3 ‘25 👇    $ARCT ARCT-032 / Cystic Fibrosis / Phase 2 » Safety findings → No SAEs, severe AEs, or dose-limiting toxicities → Dose-related increase in transient, mild, post-dose respiratory symptoms » PK findings: Very low systemic exposure → mRNA: all plas

A number of rare/genetic disease readouts are set this Q3 2025. Some of them are likely to move big. See table below for 6 of the anticipated readouts. 📈 📉

$XBI $90.78 | -3.17% Table of Contents: Top 10 Daily Positive Movers Top 10 Daily Negative Movers Top 10 Daily Volume Movers Want to...

$XBI $90.78 | -3.17% Table of Contents: Top 10 Daily Positive Movers Top 10 Daily Negative Movers Top 10 Daily Volume Movers Want to...

(Posted 10:20am CST) $XBI $93.28| -0.47% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

(Posted 10:20am CST) $XBI $93.28| -0.47% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

$XBI $68.78 | -3.25% BPIQ median | -1.84% Big Positive Movers on News #TXMD +364% TherapeuticsMD and EW Healthcare Partners Announce...

$XBI $68.78 | -3.25% BPIQ median | -1.84% Big Positive Movers on News #TXMD +364% TherapeuticsMD and EW Healthcare Partners Announce...

For our current month's Big-Mover stocks to watch after June 2021, go to https://bit.ly/2UFVnBh. Summary Every month we identify biotech...